Genetics of Susceptibility to Sporadic Ovarian Cancer

Venkata S Katabathina, University of Texas Health Science Center, San Antonio, Texas, USA
Srinivasa R Prasad, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Published online: February 2013

DOI: 10.1002/9780470015902.a0023853

Specific abnormalities involving TP53, BRCA 1, BRCA 2, KRAS, BRAF, ERBB2, PIK3CA, PTEN, CTNNB1 and ARID1A genes are responsible for the development of sporadic ovarian epithelial carcinoma (OEC). Recent advances in the field of cytogenetics and molecular biology have led to the development of an innovative classification of OEC that integrates the anatomical, clinical findings with molecular abnormalities and helps in prognostification and assessment of treatment response. TP53 and BRCA 1 and BRCA 2 gene mutations are associated with high-grade serous and high-grade endometrioid subtypes and KRAS, BRAF, ERBB2, PIK3CA, PTEN, CTNNB1 and ARID1A alterations are responsible for the development of low-grade serous, low-grade endometrioid, clear cell and mucinous subtypes of OEC. Tumours with TP53 mutations uniformly carry a worse prognosis and the presence of BRCA 1 and 2 mutations predicts the positive treatment response to platinum compounds and Poly adenosine diphospahate (ADP) ribose polymerase (PARP) inhibitors. Evolving knowledge regarding the role of different genetic abnormalities in the oncogenesis of sporadic OEC may lead to the identification of ‘small molecules’ that can be used in the discovery of new drugs as well as biomarkers for screening, prognosis, and therapeutic response in the near future.

Key Concepts:

  • Ovarian epithelial carcinoma is categorised into two subgroups designated type 1 and type 2, which differ significantly in the pathogenesis, clinic-biologic behaviour, and prognoses.
  • Type 1 tumours are genetically stable and display mutations involving different genes including KRAS, BRAF, ERBB2, PTEN, PIK3CA, CTNNB1 and ARID1A.
  • Type 2 tumours are genetically highly unstable and harbour TP53, BRCA 1 and BRCA 2 mutations.
  • High-grade serous carcinoma and low-grade serous carcinomas develop from fallopian tube epithelium and serve as the prototypes of type 2 and type 1 pathway respectively.
  • Low-grade endometrioid carcinomas and clear cell carcinomas commonly develop from endometriotic cysts.
  • The presence of TP53 mutations correlates with high grade tumours and poor prognosis.
  • The presence of mutations of BRCA 1 and BRCA 2 genes indicate good treatment response to platinum compounds and PARP inhibitors.

Keywords: TP53; BRCA 1; BRCA 2; KRAS; BRAF; PTEN; ovarian epithelial carcinomas

Figure 1. Flow chart illustrates pathogenesis of ovarian serous carcinomas. Type 1 ovarian tumours are secondary to KRAS, BRAF and ERBB2 mutations. Type 2 tumours are secondary to TP53, BRCA1 and BRCA 2 mutations. STICs, Serous tubal intraepithelial carcinomas.
Figure 2. Flow chart illustrates pathogenesis of ovarian endometrioid and clear cell carcinomas.
Figure 3. Flow charts showing normal function of p53 (on left hand side) and pathogenesis high-grade ovarian carcinomas (type 2 tumours) secondary to mutations of TP53 (on right hand side).
Figure 4. Flow chart showing the role of MAP kinase and PI3K/AKT pathways in the control of cell proliferation. Mutations of KRAS, BRAF, ERBB2, PI3K and PTEN genes promote tumour initiation and progression via upregulation of these pathways resulting in the development of type 1 OEC.
close
 References
    Banerjee S and Kaye S (2011) PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Current Oncology Reports 13(6): 442–449.
    Ferte C, Andre F and Soria JC (2010) Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nature Reviews Clinical Oncology 7(7): 367–380.
    Fresno Vara JA, Casado E, de Castro J et al. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews 30(2): 193–204.
    Guan B, Wang TL and Shih IeM (2011) ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Research 71(21): 6718–6727.
    Kalamanathan S, Bates V, Lord R and Green JA (2011) The mutational profile of sporadic epithelial ovarian carcinoma. Anticancer Research 31(8): 2661–2668.
    Katagiri A, Nakayama K, Rahman MT et al. (2012) Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Modern Pathology 25(2): 282–288.
    Koutsaki M, Zaravinos A and Spandidos DA (2012) Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form. Pathology Oncology Research 18(2): 135–148.
    Kuhn E, Kurman RJ, Vang R et al. (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma – evidence supporting the clonal relationship of the two lesions. Journal of Pathology 226(3): 421–426.
    Kurman RJ and Shih IeM (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. International Journal of Gynecological Pathology 27(2): 151–160.
    Kurman RJ and Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology 34(3): 433–443.
    Kurman RJ and Shih IeM (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Human Pathology 42(7): 918–931.
    Lowery WJ, Schildkraut JM, Akushevich L et al. (2012) Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. International Journal of Gynecological Cancer 22(1): 9–14.
    Lynch HT, Casey MJ, Snyder CL et al. (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Molecular Oncology 3(2): 97–137.
    Malpica A, Deavers MT, Lu K et al. (2004) Grading ovarian serous carcinoma using a two-tier system. American Journal of Surgical Pathology 28(4): 496–504.
    Mazzoletti M and Broggini M (2010) PI3K/AKT/mTOR inhibitors in ovarian cancer. Current Medicinal Chemistry 17(36): 4433–4447.
    McCoy ML, Mueller CR and Roskelley CD (2003) The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reproductive Biology and Endocrinology 1: 72.
    Morin PJ (1999) Beta-catenin signaling and cancer. BioEssays 21(12): 1021–1030.
    Palacios J and Gamallo C (1998) Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Research 58(7): 1344–1347.
    Pearson G, Robinson F, Beers Gibson T et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine Reviews 22(2): 153–183.
    Prat J (2012) New insights into ovarian cancer pathology. Annals of Oncology 23(Suppl. 10): x111–x117.
    Seidman JD and Khedmati F (2008) Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumours. Archives of Pathology and Laboratory Medicine 132(11): 1753–1760.
    Shih IeM and Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. American Journal of Pathology 164(5): 1511–1518.
    Siegel R, Naishadham D and Jemal A (2012) Cancer statistics. Cancer Journal for Clinicians 62(1): 10–29.
    Vang R, Shih IeM and Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Advances in Anatomic Pathology 16(5): 267–282.
    Venkitaraman AR (2001) Functions of BRCA1 and BRCA2 in the biological response to DNA damage. Journal of Cell Science 114(Pt 20): 3591–3598.
    Vereczkey I, Serester O, Dobos J et al. (2011) Molecular characterization of 103 ovarian serous and mucinous tumours. Pathology Oncology Research 17(3): 551–559.
    Weberpals JI, Koti M and Squire JA (2011) Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genetics 204(10): 525–535.
    Wiegand KC, Shah SP, Al-Agha OM et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. New England Journal of Medicine 363(16): 1532–1543.
    Wu R, Zhai Y, Fearon ER and Cho KR (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Research 61(22): 8247–8255.
    Yamamoto S, Tsuda H, Takano M, Tamai S and Matsubara O (2012) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Modern Pathology 25(4): 615–624.
    Zikan M, Janatova M, Pavlista D and Pohlreich P (2007) High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer. Journal of Genetics 86(2): 169–171.
 Further Reading
    Aghmesheh M, Suo Z, Friedlander M et al. (2006) Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. Pathology 38(2): 145–151.
    Braem MG, Schouten LJ, Peeters PH et al. (2011) Genetic susceptibility to sporadic ovarian cancer: A systematic review. Biochimica et Biophysica Acta 1816(2): 132–146.
    Jazaeri AA (2009) Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Molecular Oncology 3(2): 151–156.

Related Sub-Topics:

Cell Biology of Cancer | Cancer Genetics
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Genetics of Susceptibility to Sporadic Ovarian Cancer
 
How to Cite close
Katabathina, Venkata S, and Prasad, Srinivasa R(Feb 2013) Genetics of Susceptibility to Sporadic Ovarian Cancer. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0023853]